- Improving national medical costs and fiscal structures by preventing diabetic foot amputations
- Securing a foothold for expansion across South America… Leaping toward a global organ regeneration platform

ROKIT Healthcare (376900, CEO Seokhwan You), a specialist in AI-driven hyper-personalized organ regeneration platforms, announced on the 17th that it has successfully completed 100 cases of AI-driven hyper-personalized diabetic foot ulcer (DFU) regenerative treatment at hospitals under the Paraguayan Ministry of Public Health and Social Welfare and the Social Insurance Institute (IPS). Notably, no side effects were reported across all 100 treatment cases.

This achievement is particularly significant as it validates the company’s technological prowess through successful outcomes in official treatment cases where the national government budget was actually executed.

The treatment utilizes AI-driven precision analysis to evaluate the dimensions and characteristics of a patient’s wound and output customized regenerative patches. By moving away from traditional methods that rely heavily on the individual skill levels of medical staff, ROKIT Healthcare has enabled standardized, high-performance clinical results. This success proves that the company’s regenerative medicine model is sustainable even within public healthcare systems that may face infrastructure challenges compared to developed nations.

Paraguay has an estimated 352,000 adult diabetic patients. DFU, a severe complication of diabetes, often leads to high rates of amputation and mortality if infection or necrosis occurs. Through these successful cases, ROKIT Healthcare is spearheading a paradigm shift from an "amputation-centric" approach to a "regeneration and preservation-centered" system.

Local health officials commented, "The efficiency of our public healthcare system has significantly improved by drastically reducing amputations and lowering the burden on hospital beds and surgical resources." Leveraging its success in Paraguay as a symbolic national milestone, ROKIT Healthcare is currently expanding its market presence across South America, including Argentina and Peru.

A representative from ROKIT Healthcare stated, "Achieving 100 cases in Paraguay with zero side effects is more than just a clinical figure; it is a practical demonstration of how an AI-driven organ regeneration platform can maximize the efficiency of a national public healthcare system. We aim to establish this as a global standard for regenerative treatment, offering patients at risk of amputation a new lease on life while creating economic value through the reduction of medical costs."

The company added, "We will continue to focus on resolving global medical inequality and ensuring patients can return to their daily lives without the fear of amputation, driven by our hyper-personalized organ regeneration platform that integrates AI-driven technology and bioprinting."